$TER

MATZ MARILYN sold $508K of TER

MATZ MARILYN sold 1,200 shares of TERADYNE, INC (TER) at $423.03 ($0.51M total) on 2026-06-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · MATZ MARILYN
Published Jun 16, 2026, 10:01 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 16, 2026, 10:06 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$TER
Neutral
high confidence
Mentioned
$TER
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TERNeutralLow
01

Why it matters

A director’s open-market sale under a pre-arranged 10b5-1 plan is typically treated as non-informational; the main trading relevance is sentiment/positioning rather than fundamentals.

02

Market read

Traders may note the insider sale for sentiment, but there is no new guidance, deal, or operational catalyst in the text.

03

What to watch

The article provides only one director sale size and does not indicate whether other insiders are buying/selling around the same window.

Relevance 4/10Novelty 6/10Timing: Filed 2026-06-16; transaction dated 2026-06-15

Background

The article is a SEC Form 4 insider transaction disclosure for Teradyne, Inc.

Company-level read

Ticker impact

$TERNeutralHigh confidence
Context

Teradyne director Marilyn Matz sold 1,200 shares at $423.03 via an open-market transaction under a pre-arranged 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this Form 4; any impact would be short-lived.

Evidence & confidence

The filing is an insider sale (not a buy), explicitly under a pre-arranged 10b5-1 plan, with no accompanying operational or guidance change disclosed.

Market effects

No sector read-across; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can coincide with internal caution; traders may still fade rallies if other selling emerges.

Key entities

  • TERADYNE, INC

    US-listed company whose director insider sale is disclosed on Form 4.

  • MATZ MARILYN

    Director who sold 1,200 shares of TER under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$FORMMedAI 8/10

FormFactor, Entegris, Penguin Solutions, Teradyne, and Marvell Technology Stocks Trade Up, What You Need To Know

Several semiconductor stocks rose after the August jobs report, which showed 162,000 nonfarm payroll jobs added, beating estimates. Despite initial expectations of a rate hike, traders rotated back into the chip sector. FormFactor (FORM) +5.3%, Entegris (ENTG) +5.6%, Penguin Solutions (PENG) +5.1%, Teradyne (TER) +4.8%, and Marvell Technology (MRVL) +6.2%. Marvell reported Q2 revenue of $2.74B, up 36.5% YoY, with strong Data Center demand. Management guided Q3 revenue at $3.15B, but revenue from

$TERMed

Teradyne Stock Plunges 15% in a Month: Should You Buy the Dip?

Teradyne (TER) shares fell 15.4% in a month, underperforming peers and sector. Challenges include customer concentration and muted demand, but AI-driven data center growth and strong Q3 guidance offset this. TER expects $1.20-$1.30B revenue and $1.85-$2.15 EPS for Q3 2026, up significantly YoY. The stock trades at a premium with a forward P/S of 9.35X.

$TERHigh

Why is Teradyne stock sliding today?

Teradyne (TER) stock fell 3.9% after Baird downgraded it to Neutral with a $420 price target, citing stretched valuation and concerns over AI and hyperscaler spending sustainability. The firm argues GPU testing catalyst is priced in and next growth drivers are too distant. TER's decline contrasts with broader market gains, highlighting company-specific pressures.

$METAMed

Stocks making the biggest moves midday: Meta, Amylyx, Baidu, Klarna, Coherent, Sandisk & more

Amylyx Pharmaceuticals shares rose 53% after its avexitide treatment met trial endpoints. Meta Platforms fell 3% amid a lawsuit. Carvana dropped 3% after director stock sales. UGI Corporation surged 12% on a $9B KKR bid report. AI-related stocks declined. Klarna fell 21% on weak guidance. Baidu dropped 12% on earnings miss. Home Depot rose slightly on earnings beat. Fabrinet fell 20% on margin concerns. Memory stocks declined. Duolingo rose 7% on an upgrade.